The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A retrospective study assessing the value of MRD assessment in AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, comments on the value of measurable residual disease (MRD) assessment in light chain (AL) amyloidosis. A multi-center European retrospective study elucidated that, in patients with hematologic complete remission (CR) after initial therapy, achieving MRD negativity was associated with improved time to next treatment (TTNT) and progression-free survival (PFS). Therefore, Dr Sanchorawala suggests that MRD assessment may present a novel endpoint for clinical trials in AL amyloidosis. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The next important research that is going to be presented here is assessment of measurable residual disease in AL amyloidosis. This is a multi-center European retrospective study of 319 patients with AL amyloidosis who were suspected to have hematologic complete remission (CR) after initial therapy. And MRD assessment was done by next-generation flow cytometry, or Euroflow, and 43% of patients were MRD negative...
The next important research that is going to be presented here is assessment of measurable residual disease in AL amyloidosis. This is a multi-center European retrospective study of 319 patients with AL amyloidosis who were suspected to have hematologic complete remission (CR) after initial therapy. And MRD assessment was done by next-generation flow cytometry, or Euroflow, and 43% of patients were MRD negative. Time to next treatment and progression-free survival were better for those who achieved MRD negativity compared to those who achieved MRD positivity. And the organ responses were not different but there was a trend with better responses with MRD negativity. The time to next treatment and progression were reduced by 59% in patients who had MRD negativity with a hazard ratio of 0.44. So again, MRD assessment is not yet there but should be considered as a therapeutic endpoint for clinical trials in AL amyloidosis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, Nexcella: Membership on an entity’s Board of Directors or advisory committees; Pfizer, Janssen, Attralus, GateBio, Abbvie, BridgeBio: Consultancy; Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion: Research Funding.
